It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

High Risk Prostate Cancer Hormone and Radiation Therapy Treatment Study

Clinical Trial Title: 
Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: A phase III randomized trial.
Clinical Trial Protocol ID: 
14043003
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

The effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles will be compared with hormone therapy and radiation therapy to the whole pelvic area in prostate cancer to find out which is better.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of adenocarcinoma of the prostate.
  • Have no lymph node or bone metastases.
  • Have no other malignancy within 3 years with the exception of non-melanoma skin cancer.
  • Have no prior pelvic radiation.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-0836
Contact Name: 
Adrianne Kajmowicz, RN, BSN